Business
PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery
SHIELD I Study did not Achieve its Primary Endpoint of Reduction in Surgical Site Infections and Mortality In an FDA Requested Pre-specified Subgroup Analysis
About this update from Polypid Ltd.
[{"type":"text","content":"SHIELD I Study did not Achieve its Primary Endpoint of Reduction in Surgical Site Infections and Mortality In an FDA Requested Pre-specified Subgroup Analysis in Subjects with Incision Lengths over 20 centimeters (n=423), D-PLEX100 + SoC Achieved a Statistically Significant Reduction of 54 percent on the Primary Endpoint versus SoC alone (p20 centimeters, the local administration of D-PLEX100 resulted in a statistically significant reduction of 54 percent on the primary endpoint, compared to SoC alone (p","length":563,"tagName":"div"}]